How did IGC Pharma's revenue and expenses shift in Q3 2025?

IGC Pharma's financials for Q3 2025 are not currently available. However, insights into the company's financial shifts and recent investments are provided based on relevant news and financial reports.

1. **Investment and Strategic Moves**:
- IGC Pharma secured a $475,000 investment from its advisors through a Share Purchase Agreement. This investment is set to support general corporate activities and the advancement of the CALMA Phase 2 clinical trial for Alzheimer's disease.
- The issuance of 1,583,333 unregistered common shares is subject to a six-month trading lockup period, indicating a strategic move to bolster the company's financial position and clinical trial initiatives.
2. **Financial Positioning and Future Outlook**:
- The investment is a significant vote of confidence from the advisors, underscoring IGC Pharma's mission to innovate Alzheimer's treatment and transform the landscape of the disease.
- IGC Pharma's CEO, Ram Mukunda, has expressed optimism about the strategic investment and the company's ongoing efforts to execute its strategy across Alzheimer's and metabolic disorders, aiming to deliver transformative therapies and drive long-term value for shareholders.

While specific revenue and expense details for Q3 2025 are not available, the company's strategic investment and future projections suggest a positive trajectory, focusing on advancing its clinical trials and addressing unmet medical needs in Alzheimer's disease.